These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35347342)

  • 41. Cyclosporine A for induction of remission in severe ulcerative colitis.
    Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients: an Evidence-based Clinical Review.
    Simadibrata M; Halimkesuma CC; Suwita BM
    Acta Med Indones; 2017 Oct; 49(4):363-368. PubMed ID: 29348389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Placebo Rates in Randomized Controlled Trials of Proctitis Therapy: A Systematic Review and Meta-Analysis Placebo Response in Proctitis.
    De Silva TA; Alphonsus L; Ma C; Hogan M; Sedano R; Narula N; Danese S; Peyrin-Biroulet L; MacDonald JK; Singh S; Jairath V
    J Crohns Colitis; 2023 Jan; 17(1):123-136. PubMed ID: 35930405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A systematic review of the clinical effectiveness of azathioprine in patients with ulcerative colitis].
    Ohno K; Masunaga Y; Ogawa R; Hashiguchi M; Ogata H
    Yakugaku Zasshi; 2004 Aug; 124(8):555-60. PubMed ID: 15297725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.
    Mosli MH; MacDonald JK; Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; Khanna R; Feagan BG
    Inflamm Bowel Dis; 2015 May; 21(5):1151-9. PubMed ID: 25844963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis.
    Park S; Abdi T; Gentry M; Laine L
    Am J Gastroenterol; 2016 Dec; 111(12):1692-1701. PubMed ID: 27725645
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.
    Suilik HA; Jaber F; Abuelazm M; Ramadan A; Elzeftawy MA; Elrosasy A; Youssef RA; Abdelazeem B; Hashash JG; Farraye FA; Ghoz H
    Inflamm Res; 2024 Feb; 73(2):183-198. PubMed ID: 38153524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials.
    Chande N; MacDonald JK; Wang JJ; McDonald JW
    Inflamm Bowel Dis; 2011 Sep; 17(9):1979-86. PubMed ID: 21618363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007571. PubMed ID: 19160337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.
    Chen X; Hou J; Yuan Y; Huang C; Liu T; Mo C; Li H; Chen B; Xu Q; Hou Z; He W; Liu F
    BioDrugs; 2016 Jun; 30(3):207-17. PubMed ID: 27120055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis.
    Kornbluth AA; Salomon P; Sacks HS; Mitty R; Janowitz HD
    J Clin Gastroenterol; 1993 Apr; 16(3):215-8. PubMed ID: 8099363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
    Zhu Y; Tang RK; Zhao P; Zhu SS; Li YG; Li JB
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):487-94. PubMed ID: 22465970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis.
    Costello SP; Soo W; Bryant RV; Jairath V; Hart AL; Andrews JM
    Aliment Pharmacol Ther; 2017 Aug; 46(3):213-224. PubMed ID: 28612983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
    Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
    Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Sutherland L; Macdonald JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD000544. PubMed ID: 16625537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.